RBP 是由肝臟合成的一種低分子量蛋白,廣泛存在于人體血清、腦脊液及其他體液中。血液中RBP主要以視黃醇、前白蛋白結(jié)合復(fù)合物形式存在,當(dāng)復(fù)合物中視黃醇與 靶細(xì)胞結(jié)合后,RBP便與前白蛋白分離,自腎小球?yàn)V出,幾乎完全由近端腎小管上皮細(xì)胞吸收、降解,腎臟濾過(guò)功能受損害時(shí),RBP濃度水平會(huì)顯著升高。本研 究表明在化療前,RBP水平與對(duì)照組無(wú)明顯差異,化療后,RBP水平明顯升高,與化療前和對(duì)照組相比差異有統(tǒng)計(jì)學(xué)意義。RBP水平變化早于BUN、Cr, 且RBP水平變化與eGFR呈明顯負(fù)相關(guān),表明RBP水平可敏感地反映腎臟的損害程度,可作為監(jiān)測(cè)病程、指導(dǎo)治療和判斷預(yù)后的一項(xiàng)靈敏的、穩(wěn)定可靠的生化 指標(biāo)[10]。同時(shí)本研究也發(fā)現(xiàn),在第二周期化療后,RBP升高并不顯著,與第一周期相比差異無(wú)統(tǒng)計(jì)學(xué)意義。原因可能為RBP主要由肝細(xì)胞粗面內(nèi)質(zhì)網(wǎng)合 成,體內(nèi)90%的RBP與視黃醇結(jié)合,稱為holo-RBP,85%的holo-RBP與前白蛋白(PA)結(jié)合,形成大分子物質(zhì),不能被腎小球慮過(guò),而剩 下的15%可自由通過(guò)腎小球,正常情況下能被腎小管重吸收。當(dāng)腎功能受損時(shí),腎小管不能重吸收holo-RBP,導(dǎo)致血清RBP下降。
綜上所述,在化療過(guò)程中實(shí)時(shí)檢測(cè)腫瘤患者血清的CysC、RBP,尤其CysC的檢測(cè),可有效對(duì)腫瘤患者進(jìn)行化療時(shí)所造成的早期腎損傷進(jìn)行監(jiān)測(cè),在指導(dǎo)化療用藥、防止化療所致腎損害的進(jìn)一步發(fā)展和早期治療方面有著非常重要的應(yīng)用價(jià)值。
參考文獻(xiàn) 醫(yī).學(xué)全.在.線網(wǎng)站payment-defi.com
[1] Conti M, Moutereau S, Zater M, et al. Urinary cystatin C as a specific marker of tubular dysfunction[J].Clin Chem Lab Med, 2006, 44(12): 288-291.
[2] Babooled K,Meyer T M.The effecf of aaite angiotrnsim Ⅱ. Blockade on renal function in rats with reduced renal mass[J].Kidney Int,2002, 46 (4):980-985.
[3] Kintzel P E.Anticancer drug-induced kidney disorders:Incidence,prevention and management[J]. Drug Saf,2001,24(4):19-38.
[4] Tanaka A, Suemaru K, Otsuka T, et al. Estimation of the initial dose setting of vancomycin therapy with use of cystatin C as a new marker of renal function[J].Ther Drug Monit,2007,29(2):261-264.
[5] 陶琳,劉冰,邵鳳民.慢性腎臟病患者血清胱抑素C 測(cè)定臨床觀察及意義[J].中華實(shí)用診斷與治療雜志,2010,24(9):862-864.
[6] Tanaka A, Suemaru K, Araki H .A new app roach f or evaluating renal function and its practical application[J].J Pharmacol Sci, 2007,105(1):1-5.
[7] Mendiluce A,Bustamante J,Martin D,et al.Cystatin C as a marker of renal Function in kidney transplant patients[J].Transplant Proe,2005,37(9):3844-3847.
[8] Herget-Rosenthal S, Marggrat G, Husing J,et a1.Early detection of acute renal failure by serum cystatin C[J].Kidney Int,2004, 66(3):1115-1122.
[9] Ahlstrom A,Tallgren M,Peltonen S,et a1.Evaluation and predictive power of serum cystatin C in acute renal failure[J].Clin Nephro1,2004,62(5):344-350.
[10] Chantrel F,Agin A,Offner M,et al.Comparison of cystatin c versus creatinine for detection of mild renal failure[J].Clin Nephrol,2000,54(5):374-381.